All American Gold Corp. (AAGC)

CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is June - May.

Fiscal Year	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009
Period Ending	May 31, 2013	May 31, 2012	May 31, 2011	May 31, 2010	May 31, 2009
Selling, General & Admin	0.04	1.08	0.07	0.05	0.02
Operating Expenses	0.04	1.42	0.38	0.07	0.02
Operating Income	-0.04	-1.42	-0.38	-0.07	-0.02
Interest Expense	-0	-0.11	-0.01	-0	-0
Currency Exchange Gain (Loss)	-	-0	0	0	-0
Other Non Operating Income (Expenses)	-0.01	-0.06	-0.02	-0.01	-0
EBT Excluding Unusual Items	-0.05	-1.59	-0.41	-0.08	-0.02
Other Unusual Items	-	-0.07	-	-	-
Pretax Income	-0.05	-1.67	-0.41	-0.08	-0.02
Net Income	-0.05	-1.67	-0.41	-0.08	-0.02
Net Income to Common	-0.05	-1.67	-0.41	-0.08	-0.02
Shares Outstanding (Basic)	97	96	92	72	72
Shares Outstanding (Diluted)	97	96	92	72	72
Shares Change (YoY)	0.60%	4.82%	27.28%	-	-
EPS (Basic)	-0.00	-0.02	-0.00	-0.00	-0.00
EPS (Diluted)	-0.00	-0.02	-0.00	-0.00	-0.00
EBIT	-0.04	-1.42	-0.38	-0.07	-0.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.